nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Erythema—Thiotepa—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Lacrimation increased—Epirubicin—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Doxorubicin—urinary bladder cancer	0.00362	0.00362	CcSEcCtD
Gadoteridol—Rhinitis—Gemcitabine—urinary bladder cancer	0.00362	0.00362	CcSEcCtD
Gadoteridol—Nausea—Mitomycin—urinary bladder cancer	0.0036	0.0036	CcSEcCtD
Gadoteridol—Rhinitis—Fluorouracil—urinary bladder cancer	0.00356	0.00356	CcSEcCtD
Gadoteridol—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.00355	0.00355	CcSEcCtD
Gadoteridol—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.00345	0.00345	CcSEcCtD
Gadoteridol—Bradycardia—Cisplatin—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Gadoteridol—Injection site reaction—Epirubicin—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Epirubicin—urinary bladder cancer	0.00334	0.00334	CcSEcCtD
Gadoteridol—Fluid retention—Epirubicin—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Gadoteridol—Cough—Thiotepa—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Gadoteridol—Convulsion—Thiotepa—urinary bladder cancer	0.00323	0.00323	CcSEcCtD
Gadoteridol—Hypertension—Thiotepa—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Gadoteridol—Anxiety—Thiotepa—urinary bladder cancer	0.00317	0.00317	CcSEcCtD
Gadoteridol—Injection site reaction—Doxorubicin—urinary bladder cancer	0.00316	0.00316	CcSEcCtD
Gadoteridol—Erythema—Gemcitabine—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Gadoteridol—Tinnitus—Cisplatin—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Gadoteridol—Rash maculo-papular—Epirubicin—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Gadoteridol—Flushing—Cisplatin—urinary bladder cancer	0.00312	0.00312	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Doxorubicin—urinary bladder cancer	0.00309	0.00309	CcSEcCtD
Gadoteridol—Erythema—Fluorouracil—urinary bladder cancer	0.00309	0.00309	CcSEcCtD
Gadoteridol—Fluid retention—Doxorubicin—urinary bladder cancer	0.00302	0.00302	CcSEcCtD
Gadoteridol—Erythema—Cisplatin—urinary bladder cancer	0.00293	0.00293	CcSEcCtD
Gadoteridol—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00291	0.00291	CcSEcCtD
Gadoteridol—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.00289	0.00289	CcSEcCtD
Gadoteridol—Flushing—Etoposide—urinary bladder cancer	0.00286	0.00286	CcSEcCtD
Gadoteridol—Malaise—Gemcitabine—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00276	0.00276	CcSEcCtD
Gadoteridol—Tremor—Cisplatin—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Cough—Gemcitabine—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Paraesthesia—Thiotepa—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00272	0.00272	CcSEcCtD
Gadoteridol—Hypertension—Gemcitabine—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Gadoteridol—Convulsion—Fluorouracil—urinary bladder cancer	0.00268	0.00268	CcSEcCtD
Gadoteridol—Chest pain—Gemcitabine—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Gadoteridol—Discomfort—Gemcitabine—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Gadoteridol—Malaise—Cisplatin—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Gadoteridol—Chest pain—Fluorouracil—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Gadoteridol—Dysgeusia—Etoposide—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Gadoteridol—Pain—Thiotepa—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Gadoteridol—Discomfort—Fluorouracil—urinary bladder cancer	0.0026	0.0026	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00258	0.00258	CcSEcCtD
Gadoteridol—Oedema—Gemcitabine—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Gadoteridol—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Gadoteridol—Convulsion—Cisplatin—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Gadoteridol—Oedema—Fluorouracil—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Gadoteridol—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Gadoteridol—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00249	0.00249	CcSEcCtD
Gadoteridol—Anxiety—Cisplatin—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Gadoteridol—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Gadoteridol—Discomfort—Cisplatin—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Gadoteridol—Urticaria—Thiotepa—urinary bladder cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Malaise—Etoposide—urinary bladder cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Face oedema—Epirubicin—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Abdominal pain—Thiotepa—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Body temperature increased—Thiotepa—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Hypotension—Gemcitabine—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Gadoteridol—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Gadoteridol—Oedema—Cisplatin—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Gadoteridol—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Gadoteridol—Loss of consciousness—Etoposide—urinary bladder cancer	0.00236	0.00236	CcSEcCtD
Gadoteridol—Hypotension—Fluorouracil—urinary bladder cancer	0.00236	0.00236	CcSEcCtD
Gadoteridol—Cough—Etoposide—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Gadoteridol—Convulsion—Etoposide—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Gadoteridol—Hypertension—Etoposide—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Gadoteridol—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Gadoteridol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Gadoteridol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Gadoteridol—Chest pain—Etoposide—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Gadoteridol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Gadoteridol—Discomfort—Etoposide—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Gadoteridol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00225	0.00225	CcSEcCtD
Gadoteridol—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00225	0.00225	CcSEcCtD
Gadoteridol—Hypotension—Cisplatin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Gadoteridol—Face oedema—Doxorubicin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Gadoteridol—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Gadoteridol—Pain—Gemcitabine—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Gadoteridol—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Gadoteridol—Dysphagia—Epirubicin—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Pruritus—Thiotepa—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Pain—Fluorouracil—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Paraesthesia—Cisplatin—urinary bladder cancer	0.00215	0.00215	CcSEcCtD
Gadoteridol—Dyspnoea—Cisplatin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Gadoteridol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00212	0.00212	CcSEcCtD
Gadoteridol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Gadoteridol—Diarrhoea—Thiotepa—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Gadoteridol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Gadoteridol—Hypotension—Etoposide—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Gadoteridol—Pain—Cisplatin—urinary bladder cancer	0.00204	0.00204	CcSEcCtD
Gadoteridol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Gadoteridol—Dizziness—Thiotepa—urinary bladder cancer	0.00202	0.00202	CcSEcCtD
Gadoteridol—Urticaria—Fluorouracil—urinary bladder cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Dysphagia—Doxorubicin—urinary bladder cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Gadoteridol—Sweating—Methotrexate—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Paraesthesia—Etoposide—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Dyspnoea—Etoposide—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Gadoteridol—Vomiting—Thiotepa—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Gadoteridol—Rash—Thiotepa—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Gadoteridol—Dermatitis—Thiotepa—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Gadoteridol—Headache—Thiotepa—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Gadoteridol—Body temperature increased—Cisplatin—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Gadoteridol—Pain—Etoposide—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Gadoteridol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Gadoteridol—Sweating—Epirubicin—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Gadoteridol—Pruritus—Gemcitabine—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Gadoteridol—Nausea—Thiotepa—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Gadoteridol—Feeling abnormal—Etoposide—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Gadoteridol—Pruritus—Fluorouracil—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Gadoteridol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Gadoteridol—Bradycardia—Epirubicin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Gadoteridol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00175	0.00175	CcSEcCtD
Gadoteridol—Urticaria—Etoposide—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Gadoteridol—Rhinitis—Epirubicin—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Gadoteridol—Abdominal pain—Etoposide—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Gadoteridol—Body temperature increased—Etoposide—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Gadoteridol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Gadoteridol—Tinnitus—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Gadoteridol—Sweating—Doxorubicin—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Gadoteridol—Dizziness—Fluorouracil—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Diarrhoea—Cisplatin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Gadoteridol—Vomiting—Gemcitabine—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Gadoteridol—Bradycardia—Doxorubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Gadoteridol—Rash—Gemcitabine—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Gadoteridol—Dermatitis—Gemcitabine—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Hypersensitivity—Etoposide—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Tinnitus—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Erythema—Methotrexate—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Headache—Gemcitabine—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Flushing—Epirubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Vomiting—Fluorouracil—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Rhinitis—Doxorubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Rash—Fluorouracil—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Dermatitis—Fluorouracil—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Headache—Fluorouracil—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Gadoteridol—Dysgeusia—Methotrexate—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Gadoteridol—Pruritus—Etoposide—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Gadoteridol—Nausea—Gemcitabine—urinary bladder cancer	0.00152	0.00152	CcSEcCtD
Gadoteridol—Vomiting—Cisplatin—urinary bladder cancer	0.00152	0.00152	CcSEcCtD
Gadoteridol—Rash—Cisplatin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Dermatitis—Cisplatin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Erythema—Epirubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Gadoteridol—Diarrhoea—Etoposide—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Gadoteridol—Nausea—Fluorouracil—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Gadoteridol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Tinnitus—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Flushing—Doxorubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Dysgeusia—Epirubicin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Gadoteridol—Malaise—Methotrexate—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Gadoteridol—Dizziness—Etoposide—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Gadoteridol—Nausea—Cisplatin—urinary bladder cancer	0.00142	0.00142	CcSEcCtD
Gadoteridol—Cough—Methotrexate—urinary bladder cancer	0.0014	0.0014	CcSEcCtD
Gadoteridol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Convulsion—Methotrexate—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Vomiting—Etoposide—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Erythema—Doxorubicin—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Rash—Etoposide—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Gadoteridol—Dermatitis—Etoposide—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Gadoteridol—Headache—Etoposide—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Gadoteridol—Chest pain—Methotrexate—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Gadoteridol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Gadoteridol—Malaise—Epirubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Gadoteridol—Discomfort—Methotrexate—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Syncope—Epirubicin—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Gadoteridol—Cough—Epirubicin—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Gadoteridol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Gadoteridol—Convulsion—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Gadoteridol—Nausea—Etoposide—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Gadoteridol—Hypertension—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Gadoteridol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Gadoteridol—Chest pain—Epirubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Gadoteridol—Anxiety—Epirubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Gadoteridol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Discomfort—Epirubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Gadoteridol—Malaise—Doxorubicin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Dry mouth—Epirubicin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Syncope—Doxorubicin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Oedema—Epirubicin—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Gadoteridol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Gadoteridol—Hypotension—Methotrexate—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Gadoteridol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Gadoteridol—Cough—Doxorubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Gadoteridol—Shock—Epirubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Gadoteridol—Convulsion—Doxorubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Gadoteridol—Hypertension—Doxorubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Gadoteridol—Chest pain—Doxorubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Gadoteridol—Anxiety—Doxorubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Gadoteridol—Paraesthesia—Methotrexate—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Gadoteridol—Discomfort—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Gadoteridol—Dyspnoea—Methotrexate—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Gadoteridol—Dry mouth—Doxorubicin—urinary bladder cancer	0.00116	0.00116	CcSEcCtD
Gadoteridol—Hypotension—Epirubicin—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Gadoteridol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Gadoteridol—Oedema—Doxorubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Gadoteridol—Pain—Methotrexate—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Gadoteridol—Shock—Doxorubicin—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Gadoteridol—Paraesthesia—Epirubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Gadoteridol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Gadoteridol—Dyspnoea—Epirubicin—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Gadoteridol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Gadoteridol—Hypotension—Doxorubicin—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Gadoteridol—Pain—Epirubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Gadoteridol—Urticaria—Methotrexate—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Gadoteridol—Abdominal pain—Methotrexate—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Gadoteridol—Body temperature increased—Methotrexate—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Gadoteridol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Gadoteridol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Gadoteridol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Gadoteridol—Urticaria—Epirubicin—urinary bladder cancer	0.000975	0.000975	CcSEcCtD
Gadoteridol—Pain—Doxorubicin—urinary bladder cancer	0.000971	0.000971	CcSEcCtD
Gadoteridol—Abdominal pain—Epirubicin—urinary bladder cancer	0.00097	0.00097	CcSEcCtD
Gadoteridol—Body temperature increased—Epirubicin—urinary bladder cancer	0.00097	0.00097	CcSEcCtD
Gadoteridol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000966	0.000966	CcSEcCtD
Gadoteridol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000936	0.000936	CcSEcCtD
Gadoteridol—Pruritus—Methotrexate—urinary bladder cancer	0.000928	0.000928	CcSEcCtD
Gadoteridol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000904	0.000904	CcSEcCtD
Gadoteridol—Urticaria—Doxorubicin—urinary bladder cancer	0.000902	0.000902	CcSEcCtD
Gadoteridol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000897	0.000897	CcSEcCtD
Gadoteridol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000897	0.000897	CcSEcCtD
Gadoteridol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000897	0.000897	CcSEcCtD
Gadoteridol—Pruritus—Epirubicin—urinary bladder cancer	0.000868	0.000868	CcSEcCtD
Gadoteridol—Dizziness—Methotrexate—urinary bladder cancer	0.000867	0.000867	CcSEcCtD
Gadoteridol—Diarrhoea—Epirubicin—urinary bladder cancer	0.00084	0.00084	CcSEcCtD
Gadoteridol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000836	0.000836	CcSEcCtD
Gadoteridol—Vomiting—Methotrexate—urinary bladder cancer	0.000834	0.000834	CcSEcCtD
Gadoteridol—Rash—Methotrexate—urinary bladder cancer	0.000827	0.000827	CcSEcCtD
Gadoteridol—Dermatitis—Methotrexate—urinary bladder cancer	0.000826	0.000826	CcSEcCtD
Gadoteridol—Headache—Methotrexate—urinary bladder cancer	0.000821	0.000821	CcSEcCtD
Gadoteridol—Dizziness—Epirubicin—urinary bladder cancer	0.000811	0.000811	CcSEcCtD
Gadoteridol—Pruritus—Doxorubicin—urinary bladder cancer	0.000803	0.000803	CcSEcCtD
Gadoteridol—Vomiting—Epirubicin—urinary bladder cancer	0.00078	0.00078	CcSEcCtD
Gadoteridol—Nausea—Methotrexate—urinary bladder cancer	0.000779	0.000779	CcSEcCtD
Gadoteridol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000777	0.000777	CcSEcCtD
Gadoteridol—Rash—Epirubicin—urinary bladder cancer	0.000774	0.000774	CcSEcCtD
Gadoteridol—Dermatitis—Epirubicin—urinary bladder cancer	0.000773	0.000773	CcSEcCtD
Gadoteridol—Headache—Epirubicin—urinary bladder cancer	0.000769	0.000769	CcSEcCtD
Gadoteridol—Dizziness—Doxorubicin—urinary bladder cancer	0.000751	0.000751	CcSEcCtD
Gadoteridol—Nausea—Epirubicin—urinary bladder cancer	0.000729	0.000729	CcSEcCtD
Gadoteridol—Vomiting—Doxorubicin—urinary bladder cancer	0.000722	0.000722	CcSEcCtD
Gadoteridol—Rash—Doxorubicin—urinary bladder cancer	0.000716	0.000716	CcSEcCtD
Gadoteridol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000715	0.000715	CcSEcCtD
Gadoteridol—Headache—Doxorubicin—urinary bladder cancer	0.000711	0.000711	CcSEcCtD
Gadoteridol—Nausea—Doxorubicin—urinary bladder cancer	0.000674	0.000674	CcSEcCtD
